First-Line Ribociclib Combo Yields Significant OS Benefit Vs Fulvestrant in Postmenopausal HR+, HER2- Advanced Breast Cancer
Updated findings from the phase 3 MONALESSA-3 trial identified a significant overall survival benefit among postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who were treated with ribociclib and fulvestrant vs matched placebo.
Dr. Hurvitz Discusses Therapy Options for Breast Cancer
CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer.
Dr. Schmid Discusses the KEYNOTE-522 Trial
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
Dr. Dent Discusses Immunotherapy in Early-Stage Breast Cancer
Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.
Dr. Emens Discusses Overall Survival in HER2+ Breast Cancer
Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.
Two Studies Confirm OS Benefit of CDK4/6 Inhibitors in Breast Cancer
Two studies from ESMO have potentially found treatments which can improve survival in HR-positive breast cancer.
Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.
2 Clarke Drive Cranbury, NJ 08512